NCT00560430View on ClinicalTrials.gov

Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

September 30, 2009

Study Completion Date

October 31, 2009

Conditions
HypertensionMetabolic SyndromeHypertriglyceridemia
Interventions
DRUG

telmisartan

80 mg per day, orally, weeks 1-14

DRUG

telmisartan

80 mg per day; orally, weeks 1 and 2; 160 mg per day; orally, weeks 3-14

DRUG

placebo

placebo; orally weeks 1-14

Trial Locations (2)

10115

Center for Cardiovascular Research, University Berlin, Berlin

81377

Med. Dept. 2, University Munich, Munich

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Ludwig-Maximilians - University of Munich

OTHER

NCT00560430 - Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients | Biotech Hunter | Biotech Hunter